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Abstract
Introduction: Micronutrients (vitamins and trace elements) are essential to all nutrition. For children and neonates who are
dependent upon nutrition support therapies for growth and development, the prescribed regimen must supply all essential
components. This paper aims to facilitate interpretation of existing clinical guidelines into practical approaches for the provision of
micronutrients in pediatric parenteral nutrition.Methods: An international, interdisciplinary expert panel was convened to review
recent evidence-based guidelines and published literature to develop consensus-based recommendations on practical micronutrient
provision in pediatric parenteral nutrition. Results: The guidelines and evidence have been interpreted as answers to 10 commonly
asked questions around the practical principles for provision and monitoring of micronutrients in pediatric patients. Conclusion:
Micronutrients are an essential part of all parenteral nutrition and should be included in the pediatric nutrition therapy care plan.
(JPEN J Parenter Enteral Nutr. 2020;44(suppl S2):S5–S23)
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Introduction
Micronutrients refers to all vitamins and trace elements
(TEs) known to be essential constituents of the diet that
are required to maintain fundamental metabolic functions.
A lack of any of these essential components results in
nutrient-specific deficiencies that can be symptomatic
and interfere with growth and development. Routine
provision of micronutrients from commencement of
pediatric nutrition therapy is widely recommended but is
far from universal practice. The underlying condition of the
patient may result in specific requirements for individual
micronutrients.1,2
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Providing micronutrients to patients in a parenteral
nutrition (PN) regimen requires all nutrients to be in
a form suitable for administration via the parenteral
route.3,4 Mixing everything into a single PN admixture
simplifies administration at the bedside but presents the
challenge of physical and chemical compatibility and
stability.
Incorporating >50 different chemical species, some in
an emulsified form, in the same container means that the
majority of admixtures have limited shelf-life, usually not
more than 1–7 days’ stability.3-5 PN products marketed
by different manufacturers may differ markedly in their
composition.6,7 Mixing products from different manufac-
turers and suppliers without supporting stability data is not
advisable.8
Monitoring micronutrient status is complex; whereas
an absence of water-soluble vitamins may produce visible
symptoms such as Wernicke’s encephalopathy within 2–
3 days, for many other micronutrients the deficiency picture
is more complex and slower to develop. For many patients
receiving PN, there will be concurrent enteral nutrient
intake, moderating the need for parenteral micronutrient
supplementation, although the extent of absorption may
vary. For TEs, monitoring is complex but nevertheless
important to avoid potential toxicity, notably in, for exam-
ple, patients with liver disease and patients receiving long-
term parenteral support.2,7 Furthermore, it is known that
significant but irregular amounts of TEs are present as
contaminants of the other PN products that could influence
daily dosage.9
National and international nutrition societies have
produced guidelines to assist those responsible for
prescribing PN to children and neonates and reduce
variations in practice.10-13 However, these guidelines are
large and complex documents, often covering oral, enteral,
and parenteral requirements. The availability of products
and the skill mix and experience of local staff and the
facilities at their disposal vary widely, often making it
difficult to precisely follow the official guidelines. The aim
of this paper is to bridge the gap between evidence-based
guidelines and practical application of PN at the bedside
by providing recommendations based upon our expert
consensus interpretation of published guidelines together
with links back to the evidence. It aims to provide advice
on what a PN regimen should provide and assist users
to recognize when to seek region-specific advice from
national and regional centers of excellence. The provision
of micronutrients in adults was similarly interpreted
recently.14
The micronutrients addressed are fat-soluble vitamins
(A, D, E, K), water-soluble vitamins (B and C), and TEs
copper (Cu), iodine (I), iron (Fe), selenium (Se), zinc
(Zn), chromium (Cr), manganese (Mn), and molybdenum
(Mo).
Methodology
An interdisciplinary panel was convened representing clin-
ical, pharmaceutical, laboratory, and academic input with
a focus on practical experience in provision of nutrition
therapy in neonatal and pediatric patients. Working from
existing published guidelines and evidence-based publica-
tions, supplemented by searching databases such as Med-
line and Science Direct and personal resources, the group
has attempted to answer 10 common questions to guide
clinical practice in a range of settings. The sections were
allocated to individual members of the team to prepare a
working draft to be circulated for discussion among the
group.
Terminology and Metrology
The term “supplementation” is used for the delivery of
micronutrients to cover basal needs when PN administra-
tion aims at restoring deficiencies and ongoing losses, or
when the aim is to achieve supranormal levels, including
pharmaconutrition. Dietary recommended intakes (DRIs),
will be used to indicate recommended dosages. With no
international agreement on micronutrient Units, posology
will be expressed in both microgram and micromol.15 Ten
common questions for practical consideration regarding the
use of micronutrients in pediatric PN are:
1. Which are the essential micronutrients for neonatal
and pediatric patients?
2. When and under what conditions are parenteral
micronutrients indicated?
3. Which micronutrients are important and when are
they required for neonatal and pediatric critically ill
patients?
4. Which micronutrients are important and when are
they required for neonatal and pediatric burns
patents?
5. Which micronutrients are important and when are
they required for neonatal and pediatric surgical
patients?
6. Which micronutrients are important and when are
they required for pediatric home PN (HPN) pa-
tients?
7. What are the practical considerations when provid-
ing micronutrients parenterally?
8. How and when should micronutrient status
in neonatal and pediatric patients be assessed/
monitored?
9. What are the clinical risks of providing micronutri-
ents to neonatal and pediatric patients?
10. What are the recommendations for providing mi-
cronutrients to neonatal and pediatric patients
when suitable products are unavailable?
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Table 1. Recommended Doses for Parenteral Supply of Fat-Soluble and Water-Soluble Vitamins for Preterm Infants, Infants,
and Children.
Vitamins
Preterm infant
<37 weeks’ gestation
Infant >12 months
old
Children/adolescents
1–16 years old
Vitamin A 700–1500 IU/kg/d 500–1000 IU/kg/d 500 IU/d
Thiamin B1 0.35–0.5 mg/kg/d 0.35–0.5 mg/kg/d 1.2 mg/d
Riboflavin 0.15–0.2 mg/kg/d 0.15–0.2 mg/kg/d 1.4 mg/d
Pyridoxine 0.15–0.2 mg/kg/d 0.15–0.2 mg/kg/d 1.0 mg/kg/d
Niacin 4–6.8 mg/kg/d 4–6.8 mg/kg/d 17 mg/d
Vitamin B12 0.3 μg/kg/d 0.3 μg/kg/d 1 μg/d
Pantothenic acid 2.5 mg/kg/d 2.5 mg/kg/d 5 mg/d
Biotin 5–8 μg/kg/d 5–8 μg/kg/d 20 μg/d
Folic acid 56 μg/kg/d 56 μg/kg/d 140 μg/d
Vitamin C 15–25 mg/kg/d 15–25 mg/kg/d 80 mg/d
Vitamin D 200–1000 IU/d or 80–400
IU/kg/d
400 IU/d or 40–150 IU/kg/d 400–600 IU/d
Vitamin E 2.8–3.5 mg/kg/d 2.8–3.5 mg/kg/d 11 mg/d
Vitamin K 10 μg/kg/d 10 μg/kg/d 200 μg/d
Modified with permission from ESPGHAN 2018 recommendations by Bronsky et al.1
Table 2. Suggested Parenteral Trace Element Recommendations.
Maintenance daily PN dose, μg/kg (μmol/kg)
Trace element Preterm infants Infants and children Maximum per day
Chromium – 0.2 (0.004) 0.5 (0.1)
Copper 40 (0.6) 20 (0.3) 500 (10)
Iodine 1–10 (0.01–0.1) 1.0 (0.01)
Iron 200–250 (3.6–4.5) 50–100 (0.9–1.8) 5000 (89)
Manganese 1.0 (0.02) 1.0 (0.02) 50 (1.0)
Molybdenum 1.0 (0.012) 0.25 (0.003) 5.0 (0.06)
Selenium 7.0 (0.09) 2–3 (0.03–0.04) 100 (1.3)
Zinc 400–500 (6.2–7.8) 50–250 (0.78–3.8) 5000 (78)
Modified with permission from ESPGHAN 2018 recommendations by Domellöf.2
Summary of Recommendations
Q1. Which Are the Essential Micronutrients for
Neonatal and Pediatric Patients?
1. As micronutrients are essential for optimal human
growth and development, daily provision should be
an integral part of any PN therapy.
2. The appropriate route of micronutrient adminis-
tration should be determined in an initial compre-
hensive patient assessment and included within an
interdisciplinary nutrition care plan.
3. Recommended daily vitamin and TE requirements
for PN are shown in Tables 1 and 2.
4. The underlying condition of the patientmay result in
specific requirements for individual micronutrients.
Q2. When and Under What Conditions Are
Parenteral Micronutrients Indicated?
1. Micronutrients are indicated in all pediatric PN
regimens and should be administered as early as
possible and certainly not withheld for more than a
few days.
Q3. Which Micronutrients Are Important and
When Are They Required for Neonatal and
Pediatric Critically Ill Patients?
1. Micronutrients should be an integral part of nutri-
tion therapy in the critically ill pediatric patient to re-
duce oxidative stress and support immune functions,
wound healing, and organ recovery.
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2. If clinically indicated,micronutrient status during an
ongoing inflammatory state should be assessed and
interpreted based on physical examination, dietary
history, and biomarkers unaffected by the acute
inflammatory response.
3. Clinicians should prescribe according to the individ-
ual patient requirements to address deficiencies while
avoiding toxicity.
4. The pediatric critically ill cardiac patient may re-
quire higher micronutrient supplementation, espe-
cially during long-term therapy with diuretics.
5. Significant micronutrient losses due to prolonged
continuous renal replacement therapy (CRRT) in the
critically ill should be replaced daily.
6. Special consideration regarding micronutrient sup-
plementation should be given to both obese and
undernourished critically ill children, particularly
taking account of dietary history, ideal body weight,
inflammation, and possible organ dysfunction.
Q4. Which Micronutrients Are Important and
When Are They Required for Neonatal and
Pediatric Burn Patients?
1. Burned neonatal and pediatric patients must be
assessed as early as possible for their micronutrient
needs.
2. If PN is deemed necessary, then the full range of
micronutrient supplementation should be part of
their ongoing nutrition management, both during
hospitalization and for up to 24 months after the
burn incident.
3. Vitamins A, C, and D and TEs Fe, Cu, Se, and Zn
may be significantly depleted in patients with burns,
necessitating supplementation with these specific mi-
cronutrients at doses greater than those provided in
standard products.
Q5. Which Micronutrients Are Important and
When Are They Required for Neonatal and
Pediatric Surgical Patients?
1. Clinicians must be familiar with the extent of tissue
resection and the remaining anatomy to help predict
and manage postoperative micronutrient deficien-
cies.
2. Assessment of the patient’s surgical history, includ-
ing the length of the remaining bowel, is essential
to determine whether fat-soluble vitamins are being
absorbed enterally.
3. Zn, Fe, Cu, Se, and Mn status must be assessed in
postoperative intestinal failure (IF).
4. The implementation of a standard nutrition ther-
apy protocol, including micronutrients, can improve
outcomes of necrotizing enterocolitis (NEC) in very
low-birth-weight (VLBW) infants.
Q6. Which Micronutrients Are Important and
When Are They Required for Pediatric HPN
Patients?
1. Micronutrients should be provided routinely to all
pediatric patients receiving HPN.
2. Daily micronutrient requirements for HPN are listed
under Q1 and Tables 1 and 2, but higher doses
may be necessary when there are abnormal intestinal
losses, such as post surgery.
3. Patients receiving long-term HPN need their mi-
cronutrient status monitored periodically to avoid
deficiencies and/or toxicities.
4. HPN represents an extremely diverse group of pa-
tients, for whom advice from national or regional
specialist centers will often be helpful, particularly
with practical funding and supply issues in specific
countries and regions.
Q7. What Are the Practical Considerations
When Providing Micronutrients Parenterally?
1. Clinicians should be aware of the potential stabil-
ity issues with nonroutine pediatric PN regimens
containing higher concentrations of specific nutri-
ents/micronutrients.
2. Fe may lead to destabilization of intravenous lipid
emulsion (ILE), so all-in-one (AIO) admixtures con-
taining Fe should be avoided unless stability infor-
mation is available for the specific PN formulation.
3. Addition of multivitamins to the PN bag on the day
of administration reduces the risk of degradation.
4. Protection of the PN bag from oxygen and light min-
imizes light-catalyzed oxidation of micronutrients
and has been shown to reduce mortality in preterm
infants.
5. Reliance on variable amounts of micronutrient con-
taminants in some PN components to provide the
daily PN requirement would require monitoring to
ensure adequate provision.
Q8. How and When Should Micronutrient
Status Be Assessed/Monitored?
1. Assessment of blood measurements of micronutri-
ents should be best performed in the absence of sys-
temic inflammation and should be interpreted in the
context of the clinical condition and history. Water-
soluble vitamins should be assessed more frequently
than fat-soluble vitamins.
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2. Patients suspected to have a previous micronutrient
deficiency should be initially monitored at least
monthly.
3. Patients receiving stable micronutrient supplemen-
tations can have a reduced 3-monthly frequency of
monitoring.
4. Measuring serum/plasma levels alone might not
reflect true micronutrient status.
Q9. What Are the Clinical Risks of Providing
Micronutrients to Neonatal and Pediatric
Patients?
1. To avoid the risk of deficiencies, micronutrients
should be included routinely in all neonatal and
pediatric PN regimens
2. The risk of refeeding syndrome (RFS) can be min-
imized with a nutrition care plan incorporating a
protocol for administering an immediate dose of
thiamin, restricting energy provision, and closely
monitoring electrolytes, especially serum phosphate.
3. Fe, Cu, and Mn levels should be regularly moni-
tored, especially in patients with liver disease who are
receiving long-term (or home) PN, to avoid potential
toxicity.
4. In centers using PN products and other pharmaceu-
ticals packaged in glass, aluminum levels in blood
should be checked monthly.
5. Potential hypersensitivity reactions, largely due to
excipients in certain vitamin preparations, should be
heeded.
6. In some situations, such as in premature neonates,
individual micronutrients may need to be prescribed
separately, as there is a risk that standard commercial
micronutrient productsmay provide toomuch or too
little of the other micronutrients.
Q10. What Are the Recommendations for
Providing Micronutrients When Suitable
Pediatric Products Are Unavailable
1. Maintain regular access to national society and/or
regulatory agency websites for updates on the sup-
ply/availability situation.
2. Evaluate the use of adult multivitamin/multi-TE
products at reduced doses for pediatric PN regimens.
3. If adult multivitamins are used in neonates, products
containing polysorbate 80 or 20 or propylene glycol
should be avoided.
4. Administer individual micronutrient parenteral ad-
ditives, especially the key vitamins—thiamin, folic
acid, and pyridoxine—that are required daily.
5. Consider using oral/enteral micronutrient alterna-
tive products when clinically possible.
6. Increase monitoring and awareness of micronutrient
deficiencies.
7. Document all adverse reactions related to shortages
or unavailability of pediatric products.
Q1. Why Are Micronutrients Important for PN
and When Should They Be Provided?
Answer 1: Micronutrients are essential for optimal human
growth, health, and development, necessitating daily sup-
plementation in PN regimens. Depletion can affect immune
status, lead to organ dysfunction and muscle weakness, or
impair wound healing.
Recommendations
1. As micronutrients are essential for optimal human
growth and development, daily provision should be
an integral part of any PN therapy.
2. The appropriate route of micronutrient adminis-
tration should be determined in an initial compre-
hensive patient assessment and included within an
interdisciplinary nutrition care plan.
3. Recommended daily vitamin and trace element re-
quirements for PN are shown in Tables 1 and 2.
4. The underlying condition of the patientmay result in
specific requirements for individual micronutrients.
Rationale
Micronutrients are essential to life. They function as im-
portant coenzymes and cofactors for the metabolism of
macronutrients and are usually obtained through the diet.14
Provision must be appropriate to the life stage and clinical
requirement of the patient and should be part of any nutri-
tion intervention from commencement of therapy. Patients
with insufficient gastrointestinal (GI) function, who are un-
able to maintain adequate nutrition by GI absorption, will
also have micronutrient depletion. In cases of insufficient
dietary intake, signs and clinical symptoms of micronutrient
deficiency may manifest as functional or structural abnor-
malities that may be reversed by supplementation of the
micronutrient.16,17
Many patients will have higher demands caused by
excessive losses, redistribution from circulation to tissues,
abnormalities in metabolism, or inadequate GI absorption.
In children, malabsorption conditions include short-bowel
syndrome, autoimmune enteropathies, and congenital di-
arrhea, among others. Micronutrient deficiencies can dele-
teriously affect enzyme functions and other biochemical
processes, leading to organ dysfunction, muscle weakness,
poor wound healing, and altered immune status. Deficiency
or excess of a single micronutrient may impact the avail-
ability and function of another.18 Since it is known that
reserves of most water-soluble vitamins are minimal1 and
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little is known about tissue reserves of TEs,2,19 early sup-
plementation of micronutrients seems reasonable to support
their essential roles in metabolic processes. The appropriate
route of administration should be determined in the initial
assessment and if there is a change in the clinical state of
the patient.
Micronutrient deficiency, when unrecognized, may lead
to developmental delay or organ damage,20 but there is
insufficient research to clarify which micronutrients are
critical for regular monitoring. Mild to moderate Zn de-
ficiency, but only severe vitamin A and Fe deficiencies,
appears to affect growth,21 whereas properly planned and
delivered nutrition therapy may improve growth and weight
gain.22,23 Screening for vitamin D deficiency is currently
recommended only for individuals who present with risk
factors for hypovitaminosis.24
Micronutrient-enriched enteral nutrition (EN) or oral
nutritional supplements are the preferred first option for
the provision of micronutrients in hospital. However, when
the enteral route is unavailable or inefficient, micronutrients
must be administered in PN. DRIs have been developed
in healthy populations, and as such, their application
to acutely or chronically ill patients requiring parenteral
supplementation are only estimates and should always be
considered together with a comprehensive initial assess-
ment aimed at identifying deficiencies so that preexisting
malnutrition or specific requirements can be addressed.25
Whatever the administration route, individual micronutri-
ents undergo the same metabolic and elimination pathways.
Nevertheless, when provided orally, they are regulated by
normal physiological mechanisms, whereas the parenteral
route may lead to deposition of nonphysiological levels and
chemical forms in tissues.26
The pan-European guidelines endorsed by the Euro-
pean Society for Paediatric Gastroenterology Hepatology
and Nutrition (ESPGHAN)/European Society for Clinical
Nutrition and Metabolism (ESPEN)/European Society for
Pediatric Research (ESPR)/Chinese Society for Parenteral
and Enteral Nutrition (CSPEN)27 have published evidence-
based recommendations concerning provision of micronu-
trients in PN for children. These emphasize the importance
of an interdisciplinary team developing an overall “nutri-
tion care plan”when administering PN. This should include
defined goals and an estimate of the expected duration of
PN, based upon assessment of vital signs, physical state, an-
thropometry, laboratory indices, and dietary intake.11,12,19 A
thorough initial assessment is required to determine special
needs. The consensus view is that micronutrients should be
an integral part of PN from the first day of therapy.
Q2. When and Under What Conditions are
Parenteral Micronutrients Indicated?
Answer 2: Regular administration of micronutrients is es-
sential for all hospitalized pediatric patients, and when the
oral/enteral route is not available or is insufficient, then PN
is indicated.
Recommendation
1. Micronutrients are indicated in all pediatric PN
regimens and should be administered as early as
possible and certainly not withheld for more than a
few days.
Rationale
Micronutrients are generally provided by a balanced diet
in neonates and infants by the normal progression from
breastfeeding to mixed feeding to “normal” diet; but in
patients requiring EN support and/or PN, they must be
prescribed and provided by these alternative routes.23,28
All PN regimens should include micronutrients. Regular
parenteral administration of vitamins and TEs ensures the
provision of essential substrates and cofactors involved in
many metabolic processes.
The assessment and prescription of micronutrients, as
part of a PN regimen, should ideally be performed by
an experienced interdisciplinary nutrition support team
(NST),12 including a pediatrician or neonatologist, special-
ist pharmacist, dietitian, nutrition nurse, and a medical
laboratory scientist. The NST should also be responsi-
ble for children with IF in need of long-term PN or
HPN. In some countries, care of long-term patients is
further supported by one or more national “center(s) of
excellence.”
In pediatrics, and especially neonatology, the nutrition
needs for growth and development require a higher nutrient
density in the PN admixture. Ideally, regimens should
include the “conditionally essential” amino acids: cysteine
and taurine29 contain sufficient calcium and phosphate for
skeletal development and the full range of micronutrients.27
Pediatric patients require differing amounts of the TEs Cr,
Cu, I, Mn, Mo, Se, and Zn, according to age and weight
(see Table 2, Q1), and may be particularly susceptible to Fe
deficiency, especially neonates requiring multiple frequent
blood sampling or patients requiring long-term PN with
minimal enteral intake. When Fe is required, it should be
administered separately as an intermittent infusion or as an
oral supplement.2
Q3. Which Micronutrients Are Important and
When Are They Required for Pediatric
Critically Ill Patients?
Answer 3: Micronutrients play important roles as free
radical scavengers and in supporting immune functions and
tissue repair during critical illness.
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Recommendation
1. Micronutrients should be an integral part of nutri-
tion therapy in the critically ill pediatric patient to
reduce oxidative stress and support immune func-
tions, wound healing, and organ recovery.
2. If clinically indicated,micronutrient status during an
ongoing inflammatory state should be assessed and
interpreted based on physical examination, dietary
history, and biomarkers unaffected by the acute
inflammatory response.
3. Clinicians should prescribe according to the individ-
ual patient requirements to address deficiencies while
avoiding toxicity.
4. The pediatric critically ill cardiac patient may re-
quire higher micronutrient supplementation, espe-
cially during long-term therapy with diuretics.
5. Significant micronutrient losses due to prolonged
CRRT in the critically ill should be replaced daily.
6. Special consideration regarding micronutrient sup-
plementation should be given to both obese and
undernourished critically ill children, particularly
taking account of dietary history, ideal body weight,
inflammation, and possible organ dysfunction.
Rationale
During critical illness, micronutrients play important roles
as free radical scavengers and in supporting immune func-
tions and tissue repair.30 Deficiencies may increase the
critically ill child’s susceptibility to sepsis and ventilator
support.31
The redistribution of micronutrients between tissues and
body fluids and the reduced synthesis of carrier proteins
induced by the inflammatory response syndrome result in a
significant depletion of many plasmamicronutrient concen-
trations regardless of actual body stores (Se, Zn, vitamin A,
vitamin B6, vitamin D, and vitamin C).32,33 This has impor-
tant implications for the interpretation of individual plasma
concentrations. For instance, low vitamin D concentration
is associated with worse clinical outcomes in pediatric in-
tensive care patients, but it is difficult to determine whether
a low concentration reflects a true deficiency or if it is an
epiphenomenon.30 Thiamin and folic acid have also been
reported to be reduced in congestive heart failure, sepsis,
and inflammation and during oxidative stress, whereas
the concentrations of the positive acute phase reactants
serum ferritin and ceruloplasmin increase during critical
illness, likely underestimating Fe and Cu deficiencies.33 The
interpretation of micronutrients status may further be com-
plicated by anti-inflammatory treatment counteracting the
effects of the inflammatory response syndrome. Postnatal
dexamethasone administration has been shown to increase
vitamin A concentrations (retinol and retinol-binding pro-
tein) in preterm infants.33-35 Long-term use of the diuretic
furosemide may also cause acute depletion of thiamin,
leading to exacerbation of congestive heart failure.37
Sepsis, trauma, or multiple organ failure may induce
acute renal failure (ARF).40 The principal aim of nutri-
tion therapy in ARF is to enhance immunocompetence
and improve wound healing and organ dysfunction. In-
dividual ARF patients’ nutrition requirements can vary
considerably,41 but those with underlying malnutrition will
be at increased risk of micronutrient deficiencies due
to decreased intake, malabsorption, increased utilization,
and greater losses from CRRT because of the high fluid
turnover. Prolonged CRRT can contribute to Cu deficiency,
and plasma levels of Se, Zn, and most vitamins, except
vitamin K, are also decreased, such that requirements will
generally exceed healthy recommended dietary allowance
(not daily) (RDA). Thiamin removal during CRRTmay po-
tentiate the deleterious effects of decreased thiamin levels,42
and a loading dose has been advocated upon intensive care
unit (ICU) admission,43 followed by regular intermittent
infusions during CRRT while monitoring whole-blood lev-
els. Recent evidence suggests pyridoxine and folate losses
with CRRT may be greater than earlier reported, requir-
ing higher daily supplementation and routine monitoring
of serum levels in accordance with ESPEN guidelines.44
Supplementation of vitamin C has also been proposed,41
but caution is advised because of the potential for excess
ascorbate to be converted to the toxic oxalate salt.
Childhood obesity can increase the risk of mortality in
the critically ill child,45 necessitating special considerations
for nutrition therapy in the pediatric ICU (PICU). Obesity
is an inflammatory syndrome that results in increased
blood volume, increased cardiac output, and decreased
renal and/or hepatic function, which can all affect the
metabolism of parenteral micronutrients. Previous dietary
intake of foods with low nutrient density and bariatric
surgery increase the risk of micronutrient deficiencies in
the PICU, particularly vitamin D, thiamin, folate, B12, and
Fe.46 PN dosing should be based on ideal body weight,
but because of the complex factors that affect safe and
effective administration and dosing of nutrients and other
medications, consultation with a pediatric pharmacist is
important.47
Clinicians and NSTs should address micronutrient defi-
ciencies according to the individual ICU patients’ require-
ments and prescribe accordingly. Of note, Dao reported that
supplementation of micronutrients during times of severe
illness has not demonstrated clear benefit in either survival
advantage or reduction of adverse outcomes.30 Conversely,
Berger asserted that there is evidence that a combined PN
supplement of Cu, Zn, and Se can decrease the risk of
nosocomial infections in the ICU.48 Any supplementation
of TEs at greater than RDAposologymust be accompanied
by serial monitoring of renal function and blood levels.
S12 Journal of Parenteral and Enteral Nutrition 44(suppl S2)
Table 3. Vitamin and Trace Element Requirements in Children With Burns.
Age, y Vit A, IU Vit D, IU Vit E, IU Vit C, IU Vit K, μg Folate, μg Cu, mg Fe, mg Se, μg Zn, mg
0–13
Nonburned 1300–2000 600 6–16 15–50 2–60 65–300 0.2–0.7 0.3–8 15–40 2–8
Burned 2500–5000 250–500 1000
a
0.8–2.8 60–140 12.5–25
≥13
Nonburned 200–3000 600 23 75–90 75–120 300–400 0.9 8–18 40–60 8–11
Burned 10,000 1000 1000
a
4 300–500 25–40
Vit, vitamin.
Reproduced under creative commons license (http://creativecommons.org/licenses/by/4.0/) from Clark et al.50
aAdministered 3 times weekly.
However, standard commercial fixed-formulation products
have limitations.49
Q4. Which Micronutrients Are Important and
When Are They Required for Pediatric Burns
Patents?
Answer 4: Micronutrients are essential to improve immune
status and wound healing after burns.
Recommendation
1. Burned neonatal and pediatric patients must be
assessed as early as possible for their micronutrient
needs.
2. If PN is deemed necessary, then the full range of
micronutrient supplementation should be part of
ongoing nutrition management, both during hospi-
talization and for up to 24 months after the burn
incident.
3. Vitamins A, C, and D and TEs Fe, Cu, Se, and Zn
may be significantly depleted in burns, and nutrition
management could benefit from supplementation
with these specific micronutrients at doses greater
than those provided in standard products.
Rationale
The metabolic response of the human body to severe burn
(>40% of total body surface area [TBSA]) increases >2-
fold, leading to a hypermetabolic and hyperdynamic state.
In children, a significant increase in resting energy expen-
diture has been found to persist for up to 24 months.50,51
Protein loss, with concurrent loss of micronutrients and
insulin resistance and an increase in liver size by up to 200%,
is also reported.51
Children with burns have unique clinical and nutrition
challenges—fluid and electrolytes, energy requirements, dif-
fering body proportions, TBSA to body mass ratio, rate
of fluid loss, risk of hypothermia, nonshivering thermoge-
nesis (increased metabolic rate, oxygen consumption, and
lactate production), and thin skin—resulting in difficulties
assessing the depth of the burn.52 If nutrition therapy
is commenced early, these challenges may be addressed,
preventing impairment of wound healing, weight loss, and
immune compromise.51 Fluid retention in children may
mask loss of body mass.
Vitamins and TEs are essential from the initiation of
therapy because of their importance for the immune sys-
tem and wound healing process.50 The greatly increased
inflammatory response and consequent oxidative stress may
exceptionally deplete a number of micronutrients, including
vitamins A, C, and D (See Table 3). Vitamin A is known
to improve epithelial growth, and vitamin C is known to
enhance collagen production and cross-linking.50 Burned
skin is not able to manufacture vitamin D, and both
calcium and vitamin D homeostasis are altered because of
an increase in osteoblast apoptosis, bone resorption, and
urinary calcium loss. Additionally, the TEs Fe, Cu, Se, and
Zn are lost in burn wound cellular exudates.50
Q5. Which Micronutrients Are Important and
When Are They Required for Neonatal and
Pediatric Surgical Patients?
Answer 5: Importantmicronutrient deficiencies arising from
surgery may need specific supplementation.
Recommendation
1. Clinicians must be familiar with the extent of tissue
resection and the remaining anatomy to help predict
and manage postoperative micronutrient deficien-
cies.
2. Assessment of the patient’s surgical history, includ-
ing the length of the remaining bowel, is essential
to determine whether fat-soluble vitamins are being
absorbed enterally.
3. Zn, Fe, Cu, Se, and Mn status must be assessed in
postoperative IF.
4. A standard nutrition therapy protocol including
micronutrients can improveNECoutcome inVLBW
infants.
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Table 4. Association of Micronutrient Deficiencies With
Intestinal Surgery.
Zone of GIT resection
Potential micronutrient
deficiency
Gastric Vitamin D53,56
Vitamin K56
Iron19,53
Vitamin B1219,53
Gastric bypass Vitamin K deficiency56
Copper23
Cholecystectomy Vitamins A, D, E, and K53
Jejuno-ileal bypass Vitamins A, D, E, and K56,57
Calcium57
Pancreatico-duodenectomy Vitamins A, D, E, K, and B12
and iron58
Proximal jejunum Zinc59 and copper60
Terminal ileum Vitamin B1219,53,56,57
Extensive short bowel Vitamins B2,56 A, E, and K
and, if colon resected, folic
acid, chromium,56 zinc,
and iron19,23
GIT, gastrointestinal tract.
Rationale
Pediatric surgical patients often respond differently than
adults to the stresses of surgery. Althoughmany of the basic
principles of nutrition therapy still apply, the nature of the
surgical procedures and any specific diagnoses warrant
individual consideration. Postoperative complications
can also impact micronutrient loss, and previously
asymptomatic deficiency states may become symptomatic
following surgery. Thus, as documented in adult patients, Zn
and Se depletion has been associated with enterocutaneous
fistulae,23,53 and Se deficiency with leakage of chyle.54
Following GI surgery, an accurate clinical assessment
of the patient’s surgical history, including the length of
the remaining bowel, is essential. The presence or absence
of the ileum will determine whether long-chain fatty acids
and fat-soluble vitamins A, D, E, K, and B12 are being
absorbed enterally. Table 4 associates the zone of GI tract
resected with potential micronutrient deficiencies. Vitamin
Kdeficiencymay not bewell recognized, as the international
normalized ratio for prothrombin time lacks sensitivity and
treatment with broad-spectrum antibiotics changes the
intestinal flora, a major source of vitamin K. Irrespective
of laboratory tests, the prudent clinician should consider
additional parenteral vitamin K either by intramuscular
injection or by addition to the PN, especially prior to elective
surgery.55 Small and highly variable amounts of vitamin K
may be available from the ILE, and some of the standard
multivitamin preparations provide insufficient vitamin K.
TE deficiencies are relatively common, so assessment
should include status of Zn, Fe, Cu, and Se.60 Symptoms
that may be oberved are shown in Table 5. All outputs from
stoma, stool, and urine must be assessed in IF, as large
stool losses are associated with acidosis and micronutrient
deficiencies. Ileostomy effluent particularly contains high
levels of Zn.61 Serum Zn levels therefore need to be mon-
itored and appropriate supplementation prescribed. Since
evidence shows that Cu and Mn can accumulate in the
liver, the PN dose of standard TE supplements is commonly
halved in the presence of IF-associated liver disease, and
regular monitoring is instituted to avoid excessive Cu/Mn
toxicity while aiming to avoid deficiencies of the other
elements.
Nutrition management of pediatric IF in multidisci-
plinary centers has been instrumental in improving patient
outcomes, whereas treatment of NEC remains controver-
sial, with many different practices being employed. Using
a standard plan for feeding VLBW (<1500 g) infants
with a regimen that included micronutrients contributed to
improvements in NEC rates and infant mortality but the
authors did not separately investigate any contribution from
micronutrients.63 Some children with NEC or gastroschisis
can tolerate EN, but anorexia, feeding intolerance, and peri-
operative ileus can limit the effectiveness of EN and present
unique nutrition challenges. Small amounts of trophic EN
can be hepatoprotective for PN patients. Oral intake should
therefore be encouraged as early as possible, and whenever
feasible, the EN should contain contributorymicronutrients
for ambulatory surgical PN patients, but parenteral supply
should continue until enteral feeding is well established and
PN weaned. Cyclic PN can prevent hyperinsulinemia and
may decrease the risk of hepatic steatosis and cholestasis
in older children but is not recommended for neonates and
young children.64
Q6. Which Micronutrients Are Important and
When Are They Required for Pediatric HPN
Patients?
Answer 6: Micronutrient deficiencies can be high in long-
term HPN. Pediatric HPN patients need daily supplemen-
tation and their status monitored regularly.
Recommendation
1. Micronutrients should be provided routinely to all
pediatric patients receiving HPN.
2. Daily micronutrient requirements for HPN are listed
under Q1 and Tables 1 and 2, but higher doses
may be necessary when there are abnormal intestinal
losses, such as post surgery.
3. Patients receiving long-term HPN need their mi-
cronutrient status monitored periodically to avoid
deficiencies and/or toxicities.
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4. HPN represents an extremely diverse group of pa-
tients, for whom advice from national or regional
specialist centers will often be helpful, particularly
with practical funding and supply issues in specific
countries and regions.
Rationale
Physiological reasons for the need for micronutrients in-
clude maintenance of GI epithelial integrity and develop-
ment, but micronutrients are also important for intestinal
adaptation. Individual requirements may depend upon ges-
tational age, presence of a high-output stoma, hepatic or
renal dysfunction, and any enteral absorption. Abnormal
losses such as from fistulae and chronic inflammation
should also be considered in the individual patient require-
ments.
Without supplementation, micronutrient deficiencies are
common among pediatric patients receiving HPN. Vita-
min D, Fe, vitamin A, Zn, and Cu are among the most
common deficiencies60,65,66 and can be as high as 90% of
HPN patients.65 Rat models showed vitamin A deficiency is
associated with reduced mucosal protein and DNA content
as well as alkaline phosphatase activity.60 A nonexhaustive
list of symptoms of deficiency include cardiomyopathy (Se),
growth retardation and poor wound healing (Zn), leukope-
nia (Cu), contribution to type 2 diabetes development (Cr),
anemia (Fe), goiter (I),20 loss of vision (vitamin A), weak
muscles (vitamin B1), bleeding gums (vitamin C), osteope-
nia (vitamin D), and macrocytic anemia (vitamin B12).49
The reason for the extent of deficiencies seen can be
due to a lack of appropriate provision with standard
micronutrient parenteral supplements, limitations of solu-
bility in PN, and premature weaning from micronutrient-
containing PN. Commercially available standard supple-
ments might not deliver, for example, sufficient Zn for
premature infants.2 Equally, when there is cholestasis or
renal impairment, micronutrients such as Cu should be
reduced or removed.67
Q7. What Are the Practical Considerations
When Administering Micronutrients
Parenterally?
Answer 7: Practitioners should be cognizant of micronu-
trient contamination and consider stability/compatibility
issues when devising a PN formulation containing micronu-
trients.
Recommendations
1. Clinicians should be aware of the potential stabil-
ity issues with nonroutine pediatric PN regimens
containing higher concentrations of specific nutri-
ents/micronutrients.
2. Fe may lead to destabilization of ILEs, so AIO
admixtures containing Fe should be avoided unless
stability information is available for the particular
PN formulation.
3. Addition of multivitamins to the PN bag on the day
of administration reduces the risk of degradation.
4. Protection of the PN bag from oxygen and light min-
imizes light-catalyzed oxidation of micronutrients
and has been shown to reduce mortality in preterm
infants.
5. Reliance on variable amounts of micronutrient con-
taminants in some PN components to provide the
daily PN requirement would require monitoring to
ensure adequate provision.
Rationale
Regular daily administration of vitamins andTEs allows for
the provision of essential substrates and cofactors involved
in many metabolic processes. Micronutrients are usually
administered as part of a PN regimen or separately, if
PN is not required. Patient/caregiver convenience is usually
increased when micronutrients are incorporated in the PN,
thereby decreasing the number of infusions that must be
managed on a daily basis. Nevertheless, it is vital that
parents or caregivers are trained in aseptic techniques if
tasked with making additions of multivitamins to the PN
bag.
Stability issues related to vitamins and TEs guide how
micronutrients should be administered. When “off the
shelf”standardmultitrace and/ormultivitamin products are
used within approved stability matrices, PN admixtures are
generally safe. Institutions should employ processes to en-
sure the integrity of the additives during PN compounding
and/or administration.
Ascorbic acid (vitamin C) exhibits significant chemical
lability through oxidation within PN.68 Light and PN
packaging composition influences the rate of oxidation.69
Various B vitamins are susceptible to breakdown, such as
the chemical reduction of thiamin and photodegradation
of vitamin B2 or riboflavin (RF). RF is extremely light
sensitive and an efficient photosensitizer inducing oxidative
damage to light-exposed tissues, foods, and nutrients.70 It
absorbs both visible and UV light, is an efficient oxygen
radical sensitizer, and is a strong oxidant in its triplet
state. Consequently, UV therapy in the neonatal ICU for
hyperbilirubinemia can degrade the vitamin and lead to
RF deficiency.71 RF photosensitization is also responsible
for oxidative degradation of protein, polyunsaturated
lipids, and other vitamins such as folate, thiamin, and
ascorbate. For example, in vitro studies have demonstrated
that free radical–mediated reactions contributed to the
rapid photodegradation of up to 69.0% of methionine.72
The S–amino acid methionine protects against hepatotoxic
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agents by providing intracellular cysteine for biosynthesis
of the hepatoprotective antioxidant glutathione (GSH).
Thus, by degrading this important GSH substrate,
RF photo-oxidation can have an inhibitory effect
on amino acid uptake and may contribute to the
cytotoxicity of hepatocytes. Partial protection against
RF photosensitization is offered by specific nutrients such
as chromanols, like vitamin E, but the most simple and
effective practice is to exclude oxygen and light from the
PN system. Ribeiro et al have reported that oxidation of an
unprotected pediatric PN admixture decreases RF content
by around 40% within 6 hours and 63% in 24 hours. With
photoprotection of the PN container, residual RF remained
at 99% after 72 hours at 4 °C and 95% at 25 °C.73
Thus, destruction time of vitamins (and other nutrients)
appears dependent on the PN formula, storage, trans-
portation, and administration conditions such as light ex-
posure. To maximize the integrity of the micronutrients,
one approach utilizes adding vitamins to PN admixtures
on the day of administration, rather than at the time of
compounding, when the admixture is going to be stored at
home or within an institution, for multiple days before use.
The suggestion that administering micronutrients in ILE or
AIO PN1 protects the light-sensitive vitamins appears to
miss the point that such practice leads inevitably to light-
induced peroxidation of the lipid component. Simple light
protection of the PN system is the obvious solution and is
now a regulatory requirement in some countries.77
Administration of Fe in PN has been particularly prob-
lematic because of the trivalent cation’s destabilizing effect
on ILE. Of all PN components, iron dextran disrupted ILE
stability to the greatest extent,78 but the more recent refor-
mulated dextran products and alternative compounds, such
as iron sucrose/saccharate, may be more stable. However,
even in AIO admixtures protected by light, Fe supplemen-
tation in the presence of vitamin C causes reduction of
ferric iron to ferrous iron, leading to an increase in lipid
peroxidation, and is not recommended.79 The stability of
Fe in lipid-free 2-in-1 PN varies by formulation, with low-
protein admixtures being least stable.79 Based on rather old
data, the American Society for Parenteral and Enteral Nu-
trition (ASPEN) suggests options for supplementation of
adult PNwith iron dextran or iron sucrose, but the guideline
emphasizes the lack of stability evidence for supplementing
pediatric PN, pointing out that many hospitalized children
also receive blood transfusions, whichmay provide adequate
Fe. Compounding iron salts in AIO PN should therefore
be avoided. Administering orally or as an intermittent Fe
infusion, combined with regular monitoring of Fe status, is
preferred by the ESPGHAN guidelines.2
The necessity of additional provision of certain TEs,
such as Cr and Mn, has been questioned because of
the ubiquitous contamination of these elements within
other PN components.80 Reliance on unknown and variable
amounts of contaminants to provide these micronutrients is
still being recommended but is not a defensible policy.2 Since
neonates may be particularly vulnerable to excessive doses
of these contaminants, more research is needed to further
inform themaximum allowable levels of these contaminants
and their relative safety.
Q8. How and When Should Micronutrient
Status Be Assessed/Monitored?
Answer 8: Preexisting deficiencies/toxicities will influence
the frequency and method of monitoring.
Recommendations
1. Assessment of blood measurements of micronutri-
ents should be best performed in the absence of
systemic inflammation and should be interpreted in
the context of the clinical condition and history.
Water-soluble vitamins should be assessed initially,
more frequently than fat-soluble vitamins.
2. Patients suspected to have a previous micronutrient
deficiency should be initially monitored at least
monthly.
3. Patients receiving stable micronutrient supplemen-
tations can have a reduced 3-monthly frequency of
monitoring.
4. Measuring serum/plasma levels alone might not
reflect true micronutrient status.
Rationale
Assessment of preexisting micronutrient issues. Assessment
and interpretation of micronutrient status in critically ill
children is difficult and should ideally be delayed until the
inflammatory state is resolved and the patient’s condition
has stabilized.33
An ESPGHAN position paper on the assessment and
interpretation of vitamin and TE status in sick children was
published in 2020.81 It particularly emphasized that the use
of a multimodal approach, including clinical examination,
dietary assessment, and biomarkers, is the optimal way to
ascertain the vitamin and TE status of individual patients.
It is recommended that blood measurements of vitamins
and TEs should be best performed in the absence of an
acute inflammatory response and should be interpreted in
the context of the clinical condition and history. As a con-
sequence, it is suggested that C-reactive protein and serum
albumin level should bemeasured alongside plasma vitamin
and TE concentrations, particularly where the disease state
may result in a systemic inflammatory response.
The likelihood of pre-existing micronutrient deficiency
needs to be ascertained by a detailed history (to include
dietary, medical, and surgical). Seeing patients from
geographical areas where certain micronutrients are scarce,
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from socially disadvantaged backgrounds, or with certain
medical conditions should alert prescribers to potential
deficiencies. For example, Se deficiency in Heilongjiang
province in China, folate deficiency in patients with neural
tube defects, mixed or generalized low micronutrient
accretion in premature infants and refugees, deficiency
in fat-soluble vitamins in patients with chronic liver
disease, and changes in growth pattern might also warrant
investigation.33
Below is an indicative list of scenarios where screening
infants and children for vitamins and trace elements may
be required, based upon Gerasimidis et al (2020).81 This is
not an exhaustive list but considered typical of examples of
patients at risk.
• Clinical symptoms of malabsorption or protracted
vomiting
• Established malnutrition/growth failure
• Presence of multiple food allergies
• Long-term exclusion of major food groups; inherited
disorders of metabolism, exclusion diets
• Presence of >15% unintentional weight loss
• Medications interacting with vitamins/trace elements,
eg, folate antagonists
• Use of artificial nutrition lacking vitamins and trace
elements for >2 weeks
• Pancreatic insufficiency, eg, cystic fibrosis with poor
compliance on replacement therapy
• Long-term use of postpyloric feeding
• Presence of refeeding syndrome
• Major burns
• Major resection of small intestine or high-output
stoma
• Severe insensible losses such as severe skin disease, eg,
epidermolysis bullosa
• Severe liver disease or cholestasis
The decision to perform vitamin and trace element assess-
ments remains at the discretion of the health professionals
within the context of the clinical case.
Frequency of monitoring. Water-soluble vitamins rapidly
deplete when intake is insufficient, as they are not stored in
the body in significant amounts (apart from vitamin B12).
Deficiency can arise within 2–3 weeks of a micronutrient-
deficient diet. If a deficiency is suspected, then biochemical
monitoring should initially be no less than monthly. App-
propriate investigations are listed in Table 6.
Table 5. Typical Symptoms Observed in Deficiency States of Micronutrients.
Fat-soluble vitamins Symptoms
Vitamin A Ocular manifestations: night blindness, dry eyes, poor growth, papillary
hyperkeratosis, and impaired resistance to infections
Vitamin D Rickets (enlargement of costochondral junctions, cranial bossing, persistently
open anterior fontanelle, bowed legs, and epiphyseal enlargement)
Vitamin E Hemolytic anemia in the newborn, hyporeflexia, and spinocerebellar and
retinal degeneration
Vitamin K Prolonged bleeding and hemorrhagic manifestations
Water-soluble vitamins
Thiamin (vitamin B1)
a
Peripheral neuropathy, cardiac failure, lactic acidosis
Riboflavin (vitamin B2) Cheilosis, glossitis, corneal vascularization, and photophobia
Niacin Pellagra: diarrhea, dermatitis, dementia
Pyridoxine (vitamin B6) Microcytic anemia, seizures
Vitamin B12 Megaloblastic anemia, neurological changes
Folate Megaloblastic anemia
Vitamin Ca Scurvy, petechial hemorrhages, bleeding gums
Trace elements
Iron Microcytic anemia, irritability
Zinca Hypogonadism, growth failure, diarrhea, decreased taste acuity, hair loss, and
skin rash
Chromium Glucose intolerance
Coppera Neutropenia, anemia, neurological manifestations
Seleniuma Myalgia, cardiomyopathy
Adapted from Wong and Hardy.18
a
Deficiencies that may be more commonly apparent in the intensive care unit are shown in bold.
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Table 6. Tests for Assessing/Monitoring Micronutrients in Pediatric PN Patients.106,107
Micronutrient
a
Test
b
Comment Reference
Vitamin A (retinol) RBP and serum retinol levels Plasma RBP and the serum retinol
response to parenteral vitamin A is a
better assessment of functional vitamin
A status compared with random serum
vitamin A levels alone, as its level only
decreases when liver vitamin A storage is
severely depleted
78, 80, 86,
94
Vitamin E
(tocopherol)
Serum tocopherol level (common)
Tocopherol: total lipid ratio
(preferred)
Although tissue vitamin E level is the most
informative for vitamin E status, serum
or plasma tocopherol level is more
commonly used. Because vitamin E level
depends on plasma lipid concentrations
the vitamin E, total lipid ratio is
preferred
85
Vitamin D 25-OHD 25-OHD is considered the best biomarker
in blood
85
Vitamin K
(phytomenadione)
APTT and PTT Adequacy of vitamin K–dependent
clotting factors is normally used to
determine status using APTT and PTT
85
Vitamin B1 (thiamin) Whole-blood concentration of
thiamin (excess), erythrocyte
transketolase assay (deficiency),
urine thiamin
As thiamin is integral to carbohydrate
metabolism, those infants with lactic
acidosis receiving high quantities of
glucose would be suspected of having
thiamin deficiency
85
Vitamin B2
(riboflavin)
Vitamin B2 activation coefficient Erythrocyte glutathione reductase activity
with flavin adenine dinucleotide
treatment before and after is the method
of choice in assessing riboflavin
deficiency. Activation coefficient >1.2 is
suggestive of deficiency
85
Vitamin B6
(pyridoxine)
No single agreed best test Methods include using microbiological
assays, plasma pyridoxal-5-phosphate,
erythrocyte aspartate, and alanine
aminotransferase activity as well as a
tryptophan load test
85
Vitamin B12 Serum vitamin B12 Serum vitamin B12 is most commonly used,
although for functional studies,
measurement of methylmalonic acid
excretion is used
85
Vitamin C Plasma and leukocyte vitamin C 85
Niacin Urine N-methylnicotinamide and
N-methyl-6-pyridone-3-
carboxamide
Urinary measurement of niacin
metabolites (N-methylnicotinamide and
N-methyl-6-pyridone-3-carboxamide) is
considered the best measure of niacin
deficiency
85
Folate Red blood cells and serum folate
level
Red blood cells and serum folate level are
used to assess long-term intake
85
Zinc Serum alkaline phosphatase level,
serum zinc level
There are no sensitive markers of zinc
status, but serum alkaline phosphatase
(marker for zinc stores) is commonly
used. Results can be affected by infection
and stress as well as by exercise
85
Copper Serum copper and ceruloplasmin
levels
Marginal deficiency might be normal when
using serum copper and ceruloplasmin
levels. These may also be raised in
inflammation
77, 85
(continued)
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Table 6. (continued)
Micronutrient
a
Test
b
Comment Reference
Selenium Serum selenium (common),
glutathione peroxidase levels
(preferred)
Serum selenium indicates more recent
selenium intakes whereas erythrocyte
concentration is a marker for long-term
(120-day) intake. For functional status,
glutathione peroxidase is now preferred
85
Iodine Urine iodine (common), serum
thyroxine level, or TSH levels
(surrogate)
Iodine excretion in urine is the best method
for iodine status determination, but this
might not be available in most centers.
Surrogate measurements of serum
thyroxine level or TSH levels can be used
85
Chromium Serum levels Chromium is present in small quantities in
the body and it is extremely difficult to
measure. Serum levels may not reflect
body stores. Chromium can be also
measured in the hair
77, 85, 87
Manganese Serum levels (for deficiencies),
whole blood, or urine (for
suspected toxicity)
Serum levels should be monitored on
long-term PN, but contamination of
samples is problematic and levels might
not reflect nutrition status. If Mn
toxicity is suspected, then an MRI scan
is recommended
2, 85
Iron As part of iron study test Ferritin and hemoglobin status should be
monitored regularly in long-term PN
2, 85
25-OHD, 25-hydroxyvitamin D; APTT, activated partial thromboplastin time; MRI, magnetic resonance imaging; PN, parenteral nutrition; PTT,
prothrombin time; RBP, retinol-binding protein; TSH, thyroid stimulating hormone.
a
Red flags for possible deficiencies: malnutrition/malabsorption, complex drug therapy, complex comorbidities, high physiological demands due
to infection, surgical procedures, blood loss, or severe burns.
b
Frequencies of testing: normal pediatric patient if deficiency or toxicity symptoms clinically manifested; pediatric patient with nutrition
support—every clinical nutrition review; sick or very sick pediatric patient if deficiency or toxicity symptoms clinically manifested.
Fat-soluble vitamins, on the other hand, can bemeasured
on a 6- to 12-weekly basis80,83 in patients receiving long-term
PN.
All patients receiving long-term PN should have their TE
status monitored regularly.1,84
In centers using PN products packaged in glass, alu-
minum blood levels of pediatric PN patients should be
checked monthly (see Q9 and Answer 9)
Limitations of biochemical assessment. Clinicians need to
be aware that plasma/serum measurements might not be
appropriate for all micronutrients (see below). Note also
that inflammation might change micronutrient levels, and
pairing with C-reactive protein is recommended. Not all
micronutrients are routinely measured, and only those that
are commonly measured are listed.
Q9. What Are the Clinical Risks of Providing
Micronutrients to Neonatal and Pediatric
Patients
Answer 9: The greatest risk is not providing micronutrients
in a PN regimen.
Recommendations
1. To avoid the risk of deficiencies, micronutrients
should be included routinely in all neonatal and
pediatric PN regimens.
2. The risk of RFS can be minimized with a nutrition
care plan incorporating a protocol for administering
an immediate dose of thiamin, restricting energy
provision, and closely monitoring electrolytes, espe-
cially serum phosphate.
3. Fe, Cu, and Mn levels should be regularly mon-
itored, especially in patients with liver disease re-
ceiving long-term PN or HPN, to avoid potential
toxicity.
4. In centers using PN products and other pharmaceu-
ticals packaged in glass, aluminum levels in blood
should be checked monthly and maintained at <5
μg/kg/d.
5. Potential hypersensitivity reactions, largely due to
excipients in certain vitamin preparations, should be
heeded.
6. In some situations, such as premature neonates,
individual micronutrients may need to be prescribed
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separately, as there is a risk that standard commercial
micronutrient productsmay provide toomuch or too
little of the other micronutrients.
Rationale
Deficiency of water-soluble vitamins can occur within days
of commencing nonsupplemented PN, and stores of other
micronutrients in pediatric patients are negligible. The
greatest risk in PN therefore appears to be not providing
micronutrients routinely.
RFS, caused by overenthusiastic use of nutrition support
after a period of starvation, is potentially life-threatening,
especially in the critically ill, but unfortunately there is no
standard definition for assessment. Nevertheless, routine
laboratory markers for hypophosphatemia, hypokalemia,
and hypomagnesemia, plus clinical symptoms, indicate a
risk of cardiac, pulmonary, or GI complications and/or
organ failure. RFS and its management was reviewed by
Boateng,88 and a pediatric focus was provided by Dunn and
Fuentebella.89,90
A full assessment as part of a multidisciplinary nutrition
care plan prior to commencement of nutrition support,
with a protocol for regular monitoring of patients who
develop RFS, can potentially decrease complications and
overall mortality. Therapeutically, an immediate dose of 100
mg thiamin13,91 and thereafter maintenance doses, together
with close monitoring of calcium, magnesium, potassium,
and especially serum phosphate, minimizes the risk. How-
ever, recent trials among critically ill patients suggest supple-
mentation of electrolytes and vitamins alone is insufficient.
Energy restriction for several days and subsequent gradual
increase of energy intake is now recommended.92
Fe is an essential micronutrient but is not currently
included in most pediatric TE products. However, the
symptoms of “anemia of inflammation” such as lethargy
and tachycardia, due to the inflammatory response and/or
Fe deficiency, are relatively common in the critically ill child,
leading to loss of appetite and susceptibility to infection.93
Consequently, monitoring of Fe status and evaluating
the need for separate oral or parenteral Fe supplements
need to be included in the nutrition therapy care plan. The
destabilizing effects of Fe on lipid stability limit the amount
that can be safely incorporated into AIO admixtures.
Nevertheless, supplementation at 50–100 μg/kg/d (0.9–
1.8 μmol/kg/d), to a maximum of 5 mg/d (88 mmol/d),
is recommended.2 Most allergic reactions have been
associated with earlier iron dextran products.More recently,
reformulated product and the use of iron sucrose/saccharate
appears tominimize this risk. Nevertheless, the products are
not recommended for administration to children younger
than 4 months, and there may still be stability issues when
either product is combined with AIO admixtures.80
The most recent ESPGHAN/ESPEN/ESPR/CSPEN
guidelines provide a summary of the special
requirements and toxicity risks of excessive micronutrient
supplementation.1,2 Cu and Mn require additional
monitoring in patients with hepatic failure and/or
cholestasis, as they are known to be excreted in bile,
and levels higher than normal are potentially toxic.67
Previous recommendations to remove Cu from PN in
cholestasis, however, have been rescinded.94-97 Current
guidelines recommend 20–40 μg/kg/d (0.3–0.6 μmol/kg/d)
with a maximum of 500 μg/d (7.5 μmol/d).2 In long-term
PN, there have been reports of Mn accumulation and
toxicity, from deposition in the basal ganglia of the brain98
and neuropsychiatric symptoms.99 These occurrences are
reported to be reversible over time, upon removingMn from
the PN, but this is difficult when using a fixed-formulamulti-
TE product. With only very few published case reports of
PN-relatedMn deficiency, the need to routinely supplement
PN has been questioned.100 Nevertheless, the lower Mn
content in some of the recently reformulated commercial
products96 has partially addressed these risk concerns at
a recommended dose of no greater than 1 μg/kg/d (0.018
μmol/kg/d), to a maximum of 50 μg/d (0.9 μmol/d).2
The TE aluminum has no significant therapeutic benefits
but is present as a contaminant in some PN additives
and can accumulate to toxic levels when the GI tract is
bypassed, as in the case of neonates and patients with
renal impairment.101 Aluminum accumulation has been
associated with neurotoxicity, metabolic bone disease, and
Alzheimer disease in patients receiving long-term PN/HPN.
PN products and other potential drug additives packaged
in glass containers are more susceptible to aluminum
contamination, notably, calcium gluconate, inorganic
phosphates and cysteine hydrochloride, albumin, and
sucralfate.102
The US Food and Drug Administration (FDA) mandate
in 1986 restricting the aluminum content of large-volume
PN products to 25 μg/L was modified in 2000 to require
small-volume PN additives to be labeled with their
maximum aluminum concentration and that PN patient
levels should not exceed 5 μg/L (0.2 μmol/kg/d).103 The new
British Pharmacopoeia monograph for parenteral solutions
(volumes unspecified) is proposing a similar limit of 25
μg/L. Until all manufacturers have significantly reduced
the aluminum content of their products, it is recommended
that in centers using PN products packaged in glass, blood
levels of pediatric patients receiving long-term PN should
be checked monthly.
Although rare, there have been case reports of hypersen-
sitivity reactions believed to be due to surfactant excipients
in certain, but not all, fat-soluble vitamin products. Acute
adverse reactions have also been reported from rapid admin-
istration of large doses of some vitamins.104
Even though currently available commercial TEs and
vitamin products are convenient PN additives, beware that
they might not meet the nutrition requirements of some
S20 Journal of Parenteral and Enteral Nutrition 44(suppl S2)
pediatric populations (for example, Zn requirements for
premature neonates).2
When only one micronutrient is deficient, it may not
be appropriate to increase the total volume of admixture
to achieve requirement, as this will increase the provision
of all other micronutrient components in the admixture.
The opposite is true when one micronutrient is in the toxic
range. Micronutrient components might need to be added
individually rather than as premixed products.
Q10. What Are the Recommendations for
Providing Micronutrients to Neonatal and
Pediatric Patients When Suitable Products
Are Unavailable?
Answer 10: Resources to assist healthcare professionals
identify and manage shortages are available on the ASPEN,
American Society of Health-System Pharmacists (ASHP),
and FDA websites and from local regulatory authorities.
Recommendations
1. Maintain regular access to national society and/or
regulatory agency websites for updates on the prod-
ucts’ supply/availability.
2. Evaluate the use of adult multivitamin/multi-TE
products at reduced doses for pediatric PN regimens.
3. If adult multivitamins are used in neonates, products
containing polysorbate 80 or 20 or propylene glycol
should be avoided.
4. Administer individual micronutrient parenteral ad-
ditives, especially the key vitamins—thiamin, folic
acid, and pyridoxine—that are required daily.
5. Consider using oral/enteral micronutrient alterna-
tive products where clinically possible.
6. Increase monitoring and awareness of micronutrient
deficiencies.
7. Document all adverse reactions related to shortages
or unavailability of pediatric products.
Rationale
Nonavailability of appropriate pediatric micronutrient
products or persistent shortages can lead to inadequate
dosing and consequently nutrient deficiencies. If specific pe-
diatric micronutrient products are unlicensed in a particular
country or are unavailable because of prolonged shortages,
regulatory agenciesmay approve the temporary importation
of alternative products.
ASPEN and other national PN and EN societies contin-
uously monitor shortages of PN components through reg-
ular communications with the FDA, other regulatory agen-
cies, pharmaceutical manufacturers, professional healthcare
organizations, and clinicians.
Since 2016,ASPEN’sClinical PracticeNutrition Product
Shortage Subcommittee has developed product-shortage
recommendations to help clinicians manage PN therapy
during times of product shortages. These recommendations,
which are continuously updated, can be accessed via the
ASPEN website (www.nutritioncare.org). In essence, it is
recommended to reserve parenteral micronutrients for PN-
dependent patients and reserve pediatric products for chil-
dren. If no pediatric micronutrient products are available,
then adult products can be considered at a pro rata reduced
daily dose based on the weight of the patient. However,
it is important to be aware that some adult products may
contain levels of certain excipients and of aluminum, which
may be toxic to neonates; some adult multivitamins contain
propylene glycol and polysorbate 80 and 20 as excipients,
which could be toxic in infants born at<36 weeks’ gestation
or under 1500 g. Other organic excipients such as glycine are
not believed to be toxic. However, their use will marginally
increase the total glycine content of the PN regimen.
Clinical judgment must therefore balance the potential
risks of micronutrient deficiencies from prescribing
micronutrient-free PN against the potential toxicity from
incorporating these adult components into the PN regimen.
If neither pediatric nor adult multivitamin or multi-TE
products are available, then individual parenteral micronu-
trient products should be considered at dosages appropriate
for the patient’s age and weight. In particular, thiamin,
ascorbic acid, pyridoxine, and folic acid should be given
daily.104 Switching to oral or enteral multivitamin/multi-TE
supplements should also be considered if appropriate, with
certain provisos.
Whichever strategy is adopted, it is important to notify
patients receiving long-term PN/HPN when and how
their PN formulation has been modified by incorporating
alternative PN components. It is also advisable to increase
the frequency of monitoring of serum or other appropriate
biochemical markers for micronutrient status and to in-
crease awareness of signs and symptoms of deficiencies. All
adverse events or medication hazards related to shortages
or unavailability of micronutrients should be documented.
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